Revolution Medicines Form 4: Cislini Sells 1,799 Shares Under 10b5-1 Plan

Rhea-AI Filing Summary

Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), reported an insider sale. On 09/24/2025 he disposed of 1,799 shares of common stock at a price of $44.26 per share under a previously adopted 10b5-1 trading plan. After the sale he beneficially owned 50,425 shares in total, which the filing specifies includes 43,910 restricted stock units. The Form 4 was signed on behalf of Mr. Cislini by an attorney-in-fact on 09/26/2025.

Positive

• Sale executed under a 10b5-1 plan, indicating pre-established trading parameters
• Continued beneficial ownership of 50,425 shares, including 43,910 restricted stock units, showing retained exposure
• Timely disclosure with Form 4 filed and signed by attorney-in-fact

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider sale under a pre-established 10b5-1 plan; modest share reduction with substantial RSU holdings retained.

The filing documents a single, routine disposition of 1,799 shares at $44.26 executed pursuant to a 10b5-1 plan adopted March 13, 2025. Such plans are commonly used to provide predetermined liquidity while avoiding allegations of trading on material nonpublic information. The reported post-transaction beneficial ownership of 50,425 shares, including 43,910 restricted stock units, indicates the reporting person retains meaningful economic exposure to the company despite the sale. No other transactions, option exercises, or acquisitions are disclosed.

Corporate Governance Expert

TL;DR: Disclosure aligns with compliance best practices; execution appears administrative rather than indicative of new material information.

The Form 4 records compliance with Section 16 reporting through timely disclosure of a sale executed under a documented 10b5-1 plan. The signature was provided by an attorney-in-fact, which is common for procedural filings. The filing does not contain any indications of departures, grants, or other governance events. From a governance perspective this is a routine insider liquidity event with continued significant RSU holdings reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2025		S(1)		1,799	D	$44.26	50,425(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.

2. Includes 43,910 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	09/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Jeff Cislini report on Form 4 for RVMD?

He reported the disposal of 1,799 shares of Revolution Medicines common stock on 09/24/2025 at a price of $44.26 per share.

Was the sale part of a 10b5-1 trading plan?

Yes. The filing states the transaction was made pursuant to a 10b5-1 trading plan adopted on March 13, 2025.

How many shares does the reporting person beneficially own after the transaction?

The Form 4 reports beneficial ownership of 50,425 shares following the reported transaction, which includes 43,910 restricted stock units.

What is the reporting person's role at Revolution Medicines?

The filing identifies the reporting person as an Officer (General Counsel) of Revolution Medicines.

When was the Form 4 signed and by whom?

The signature on the form is /s/ Jack Anders, as Attorney-in-fact for Jeff Cislini dated 09/26/2025.